Shanghai Haohai Biological Tech Co (688366) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.019x

Based on the latest financial reports, Shanghai Haohai Biological Tech Co (688366) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥109.13 Million ≈ $15.97 Million USD) by net assets (CN¥5.88 Billion ≈ $861.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688366 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Shanghai Haohai Biological Tech Co - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Shanghai Haohai Biological Tech Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shanghai Haohai Biological Tech Co Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shanghai Haohai Biological Tech Co ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Jastrzebska Spotka Weglowa SA
WAR:JSW
0.130x
Veken Elite
SHG:600152
0.045x
DNA Link Inc
KQ:127120
-0.060x
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
-0.073x
Rongan Property Co Ltd
SHE:000517
0.074x
Beijing WKW Automotive Parts Co Ltd
SHE:002662
0.036x
Lg Electronics Pref
KO:066575
0.061x
Wuhan Keqian Biology Co Ltd
SHG:688526
0.042x

Annual Cash Flow Conversion Efficiency for Shanghai Haohai Biological Tech Co (2012–2024)

The table below shows the annual cash flow conversion efficiency of Shanghai Haohai Biological Tech Co from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Haohai Biological Tech Co worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.92 Billion
≈ $865.85 Million
CN¥648.57 Million
≈ $94.91 Million
0.110x +3.96%
2023-12-31 CN¥6.02 Billion
≈ $880.52 Million
CN¥634.45 Million
≈ $92.84 Million
0.105x +169.06%
2022-12-31 CN¥5.90 Billion
≈ $863.70 Million
CN¥231.30 Million
≈ $33.85 Million
0.039x -30.62%
2021-12-31 CN¥6.06 Billion
≈ $886.81 Million
CN¥342.29 Million
≈ $50.09 Million
0.056x +23.58%
2020-12-31 CN¥5.73 Billion
≈ $839.10 Million
CN¥262.07 Million
≈ $38.35 Million
0.046x -25.95%
2019-12-31 CN¥5.65 Billion
≈ $827.26 Million
CN¥348.91 Million
≈ $51.06 Million
0.062x -39.50%
2018-12-31 CN¥3.84 Billion
≈ $561.25 Million
CN¥391.28 Million
≈ $57.26 Million
0.102x +0.12%
2017-12-31 CN¥3.37 Billion
≈ $492.65 Million
CN¥343.06 Million
≈ $50.20 Million
0.102x +19.56%
2016-12-31 CN¥2.99 Billion
≈ $436.93 Million
CN¥254.49 Million
≈ $37.24 Million
0.085x -15.39%
2015-12-31 CN¥2.67 Billion
≈ $390.04 Million
CN¥268.51 Million
≈ $39.29 Million
0.101x -57.85%
2014-12-31 CN¥594.16 Million
≈ $86.94 Million
CN¥141.99 Million
≈ $20.78 Million
0.239x -11.33%
2013-12-31 CN¥545.05 Million
≈ $79.76 Million
CN¥146.91 Million
≈ $21.50 Million
0.270x -10.48%
2012-12-31 CN¥393.33 Million
≈ $57.56 Million
CN¥118.42 Million
≈ $17.33 Million
0.301x --

About Shanghai Haohai Biological Tech Co

SHG:688366 China Biotechnology
Market Cap
$839.16 Million
CN¥5.73 Billion CNY
Market Cap Rank
#9852 Global
#2622 in China
Share Price
CN¥30.15
Change (1 day)
-0.17%
52-Week Range
CN¥30.15 - CN¥57.62
All Time High
CN¥268.82
About

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more